Qinghai Spring Medicinal Resources Technology Co., Ltd.
600381.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.41 | 2.76 | -1.51 | 0.90 |
| FCF Yield | 3.56% | 0.23% | -0.45% | -3.75% |
| EV / EBITDA | -11.34 | -18.88 | -42.29 | -26.75 |
| Quality | ||||
| ROIC | -18.23% | -20.58% | -18.70% | -11.02% |
| Gross Margin | 27.24% | 60.44% | 46.11% | 19.73% |
| Cash Conversion Ratio | -0.41 | -0.09 | 0.11 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.05% | 18.74% | 8.83% | -18.24% |
| Free Cash Flow Growth | 632.22% | 131.81% | 82.42% | 32.61% |
| Safety | ||||
| Net Debt / EBITDA | 1.14 | 0.66 | 0.98 | 0.92 |
| Interest Coverage | -202.76 | -269.09 | -3,226.84 | -2,200.56 |
| Efficiency | ||||
| Inventory Turnover | 1.13 | 0.28 | 0.26 | 0.26 |
| Cash Conversion Cycle | 405.96 | 1,374.52 | 1,572.90 | 1,753.78 |